That suggests something of the likelihood of a short squeeze in shares of EXAS. During the same quarter in the prior year, the business posted ($0.36) earnings per share.
Several analysts have released their opinion on Exact Sciences Corporation (NASDAQ:EXAS), with 8 analysts believing it is a strong buy.
The company's stock is now moving with a +ve distance from the 200 day SMA of approximately 13.44%, and has a solid year to date (YTD) performance of -9.25% which means that the stock is constantly adding to its value from the previous fiscal year end price. The company operates in the Healthcare sector with a market capitalization of 5.68 Million. Benchmark maintained Exact Sciences Corporation (NASDAQ:EXAS) on Wednesday, May 31 with "Buy" rating. It has outperformed by 441.54% the S&P500.
The company's Average Earnings Estimate for the Current Fiscal quarter is $-0.25, according to consensus of 12 analysts. The Russell 2000 index of smaller-company stocks picked up 9 points, or 0.6 percent, to 1,601. After having $0.46 EPS previously, Ciner Resources LP's analysts see 19.57% EPS growth. The return on equity ratio or ROE stands at -30.3 percent while most common profitability ratio return on investment (ROI) was -49.6 percent. About 739 shares traded.
Ciner Resources LP engages in the trona ore mining and soda ash production businesses in the United States and internationally. Public Employees Retirement System of OH now owns 122,201 shares of the medical research company's stock valued at $5,758,000 after acquiring an additional 50,185 shares in the last quarter. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Ciner Resources had 5 analyst reports since April 12, 2016 according to SRatingsIntel. As per Tuesday, August 25, the company rating was maintained by Mizuho. The firm has "Buy" rating by Nomura given on Tuesday, May 3. Finally, BidaskClub cut EXACT Sciences from a buy rating to a hold rating in a research report on Tuesday, December 12th. The Nasdaq added 65 points, or 0.9 percent, to 7,326.
Since September 1, 2017, it had 0 insider buys, and 6 sales for $16.89 million activity. Its down 0.26, from 1.27 in 2017Q2. Currently, Exact Sciences Corporation (NASDAQ:EXAS) has an average volume of 1.93 Million. 44 funds opened positions while 77 raised stakes. Exact Sciences Corporation disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President and CEO Conroy Kevin T has sold 125,402 shares of Exact Sciences Corporation (EXAS) in trading session dated January 12, 2018. Piedmont Investment Advisors LLC acquired a new stake in EXACT Sciences during the 3rd quarter valued at $514,000. Exact Sciences Corporation (NASDAQ:EXAS) has a 20-Day average volume of 2.78 Million. Following the completion of the sale, the insider now owns 272,819 shares in the company, valued at approximately $14,623,098.40. -23.29% away from the high and 187.85% from the low. Fiera Cap reported 93,416 shares. Sigma Planning Corporation holds 0.02% or 6,256 shares in its portfolio. Driehaus Mgmt Ltd Com has 118,748 shares. Kornitzer Capital Mngmt Ks reported 284,340 shares. Rhumbline Advisers owns 140,967 shares for 0.01% of their portfolio. Us Bankshares De accumulated 730,669 shares. COWARD D SCOTT sold 29,115 shares worth $1.37 million. Conroy Kevin T also sold $6.62M worth of Exact Sciences Corporation (NASDAQ:EXAS) shares.
On movement of stock as RSI reading reached at 38.10 because on this mostly stock considered as overbought or oversold. Therefore 56% are positive. On Wednesday, February 22 the stock rating was upgraded by TH Capital to "Buy". California Public Employees Retirement System now owns 190,338 shares of the medical research company's stock valued at $8,969,000 after acquiring an additional 5,238 shares in the last quarter. The firm has "Hold" rating given on Wednesday, November 1 by BTIG Research. The rating was downgraded by Mizuho on Wednesday, May 4 to "Neutral". Leerink Swann has "Outperform" rating and $63 target. The firm earned "Buy" rating on Thursday, October 1 by Craig Hallum. (NASDAQ:IDSY) to report earnings on March, 1. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2018/01/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-exact-sciences-exas-stock-price-updated.html. Trading volume for Exact Sciences Corporation was 14.2 Million in its previous trading session. D-E Shaw & Company Inc who had been investing in Exact Sciences Corp (Put) for a number of months, seems to be less bullish one the $5.91 billion market cap company. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It now has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.
- Here is What Institutional Investors Think About Helmerich & Payne Inc (NYSE:HP)
- Australian Open 2018: Federer gets stiff test, American Sandgren stuns Wawrinka
- Bank of Montreal Can Increases Position in BB&T Co. (BBT)
- Rain Chances Increasing into Friday
- West Brom boss Pardew pays tribute to Cyrille Regis
- How Many Diebold Nixdorf, Incorporated (NYSE:DBD)'s Analysts Are Bullish?
- $1.01 EPS Expected for Crown Castle International Corp. (REIT)
- Activision CEO of Publishing Erich Hirshberg Stepping Down in March
- Trump Official Resigns Over Racist, Anti-Muslim And Anti-LGBT Remarks
- Reliance Retail's Q3 pre-tax profit jumps 82% to Rs 606 cr